LMAT vs. STVN, IRTC, BLCO, GKOS, TMDX, SLNO, NVST, LIVN, WRBY, and INSP
Should you be buying LeMaitre Vascular stock or one of its competitors? The main competitors of LeMaitre Vascular include Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), TransMedics Group (TMDX), Soleno Therapeutics (SLNO), Envista (NVST), LivaNova (LIVN), Warby Parker (WRBY), and Inspire Medical Systems (INSP). These companies are all part of the "medical equipment" industry.
LeMaitre Vascular vs. Its Competitors
Stevanato Group (NYSE:STVN) and LeMaitre Vascular (NASDAQ:LMAT) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.
In the previous week, LeMaitre Vascular had 4 more articles in the media than Stevanato Group. MarketBeat recorded 8 mentions for LeMaitre Vascular and 4 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 1.36 beat LeMaitre Vascular's score of 0.63 indicating that Stevanato Group is being referred to more favorably in the media.
Stevanato Group has higher revenue and earnings than LeMaitre Vascular. LeMaitre Vascular is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.
Stevanato Group has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, LeMaitre Vascular has a beta of 0.77, suggesting that its share price is 23% less volatile than the S&P 500.
LeMaitre Vascular has a net margin of 20.08% compared to Stevanato Group's net margin of 11.73%. LeMaitre Vascular's return on equity of 13.67% beat Stevanato Group's return on equity.
LeMaitre Vascular has a consensus target price of $97.60, indicating a potential upside of 8.75%. Given LeMaitre Vascular's higher probable upside, analysts clearly believe LeMaitre Vascular is more favorable than Stevanato Group.
84.6% of LeMaitre Vascular shares are owned by institutional investors. 9.5% of LeMaitre Vascular shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
LeMaitre Vascular beats Stevanato Group on 10 of the 16 factors compared between the two stocks.
Get LeMaitre Vascular News Delivered to You Automatically
Sign up to receive the latest news and ratings for LMAT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LMAT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
LeMaitre Vascular Competitors List
Related Companies and Tools
This page (NASDAQ:LMAT) was last updated on 10/22/2025 by MarketBeat.com Staff